SEATTLE, WA--(Marketwire - January 03, 2008) - Calistoga Pharmaceuticals, Inc., a biopharmaceutical company dedicated to developing innovative medicines for the treatment of cancer and inflammatory diseases, announced a modification of the Series A financing totaling $26.2 million capital raised. Current investors agreed to increase the size of the Series A investment from $21 million to $26.2 million, and accelerate the timing of funding, based on the Company’s success in moving two compounds toward the clinic. The early infusion of additional resources provides the means to accelerate and expand the Company’s clinical development plan in 2008.